Faron Pharmaceuticals: Initial phase II data - Redeye

Redeye leaves a comment following the first results published from the phase II part of the company’s ongoing BEXMAB study. We are encouraged to learn that bexmarilimab continues to show a robust safety profile and a promising response rate.

Länk till analysen i sin helhet: https://www.redeye.se/research/1009251/faron-pharmaceuticals-initial-phase-ii-data?utm_source=finwire&utm_medium=RSS